Biogen (BIIB) Q2 2026: 73% EPS Beat as Growth Portfolio Takes the Lead

As seen on the 24/7 Wall St. homepage on July 29, 2026.

BIIB Biogen
Q2 2026
EPS
$3.60
est $2.07 +73.6%
Revenue
$2.74B
est $2.46B +11.4%

Biogen's growth portfolio revenue finally surpassed its legacy MS business, propelled by a massive 73% EPS beat and momentum from the Apellis acquisition, prompting a $0.60 full-year guidance raise.

Continue ReadingShow less

Biogen reported Q2 2026 earnings per share of $3.60, well ahead of the $2.07 consensus estimate — a beat of nearly 74%. Revenue came in at $2.74 billion against an estimate of roughly $2.46 billion, a top-line beat of about 11%. The quarter also marked a structural turning point: Biogen's growth portfolio revenue surpassed its legacy multiple sclerosis business for the first time, a milestone the company has been working toward for several years.

The Apellis acquisition contributed to the momentum driving those growth-portfolio results. Management responded to the strong quarter by raising full-year guidance by $0.60, a signal of sustained confidence beyond a single outperforming period.

Looking at recent history, Biogen's beat pattern has been consistent but uneven in magnitude. The company posted reported EPS of $3.57 in Q1 2026, $1.99 in Q4 2025, and $4.81 in Q3 2025, each ahead of the respective Wall Street estimate. The Q2 2026 beat stands out as the widest margin in that run, making the guidance raise a natural focal point for investors tracking whether the growth portfolio can maintain its new lead over the MS legacy segment.

Mentioned: BIIB